- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04251182
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Design & Methods: Phase 2 multi-center, randomized, double blind, placebo-controlled study of T3D959 15 mg, 30 mg, 45 mg, or matching placebo administered orally once daily for 24 weeks. There will be equal allocation of subject numbers across the four groups. Stratified randomization will be conducted on the basis of ApoE4 genotype so that subjects are randomized into one of the four dose groups within each stratum of ApoE4 status: ApoE4-positive (at least one E4 allele) vs ApoE4-negative (no E4 alleles).
Following informed consent, subjects will enter the screening phase of the study.
Once eligibility is confirmed and before the start of the first dose of study drug, subjects will be randomized on a 1:1:1:1 basis to placebo or T3D959 treatment (15mg, 30mg, 45mg) for the 24-week treatment period. Investigators, subjects, and caregivers will be blinded to the treatment assignment.
Study schedule visits: screening, baseline, weeks 4, 8, 16, 24 and 28 (F/U visit)
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85048
- Cognitive Clinical Trials, LLC
-
Scottsdale, Arizona, United States, 85258
- Imaging Endpoints
-
-
California
-
Panorama City, California, United States, 91402
- National Research Institute
-
San Diego, California, United States, 92065
- Pacific Research Network
-
Santa Ana, California, United States, 92705
- Syrentis Clinical Research
-
Santa Ana, California, United States, 92705
- CITrials
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Mile High Research Center
-
-
Connecticut
-
Norwalk, Connecticut, United States, 06851
- Research Center for Clinical Studies
-
-
Florida
-
Hialeah, Florida, United States, 33012
- Indago Research and Health Center
-
Hollywood, Florida, United States, 33024
- Infinity Clinical Research
-
Lady Lake, Florida, United States, 32159
- Charter Research - Lady Lake
-
Maitland, Florida, United States, 32751
- ClinCloud, LLC
-
Merritt Island, Florida, United States, 32952
- Merritt Island Medical Research, LLC
-
Miami, Florida, United States, 33144
- Elite Clinical Research
-
Miami, Florida, United States, 33133
- Visionary Investigators Network
-
Miami, Florida, United States, 33133
- CCM Clinical Research Group
-
Miami, Florida, United States, 33155
- Allied Biomedical Research Institute
-
Miami, Florida, United States, 33176
- Miami Dade Medical Research Institute, LLC
-
Miami, Florida, United States, 33122
- Premier Clinical Research Institute, Inc.
-
Miami, Florida, United States, 33137
- Miami Jewish Health
-
Miami, Florida, United States, 33176
- The Neurology Research Group
-
Miami, Florida, United States, 33015
- Health Care Family Rehab and Research Center
-
Miami, Florida, United States, 33155
- Global Life Research
-
New Port Richey, Florida, United States, 34652
- Suncoast Clinical Research
-
Orlando, Florida, United States, 32819
- Headlands Research Orlando
-
Palm Beach Gardens, Florida, United States, 33410
- Advanced Research Consultants
-
Palmetto Bay, Florida, United States, 33157
- IMIC Research
-
Pembroke Pines, Florida, United States, 33026
- Visionary Investigators Network
-
Tampa, Florida, United States, 33615
- Santos Research Center
-
Viera, Florida, United States, 32940
- ClinCloud Clinical Research
-
-
Georgia
-
Decatur, Georgia, United States, 30030
- iResearch Atlanta
-
Gainesville, Georgia, United States, 30501
- Center for Advanced Research & Education
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96817
- Hawaii Pacific Neuroscience
-
-
Indiana
-
Anderson, Indiana, United States, 46011
- Community Hospital of Anderson and Madison County Inc.
-
Avon, Indiana, United States, 46123
- American health Network-Avon
-
-
Maryland
-
Baltimore, Maryland, United States, 21208
- PharmaSite Research
-
-
Nevada
-
Las Vegas, Nevada, United States, 89128
- Neurology Center of Las Vegas
-
-
New York
-
Amherst, New York, United States, 14226
- Dent Neurologic Institute
-
Brooklyn, New York, United States, 11229
- Integrative Clinical Trials, LLC
-
East Syracuse, New York, United States, 13057
- Clarity Clinical Research
-
New York, New York, United States, 10036
- Manhattan Behavioral Medicine
-
Staten Island, New York, United States, 10314
- Richmond Behavioral Associates
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28270
- ANI Neurology, PLLC dba Alzheimer's Memory Center
-
Charlotte, North Carolina, United States, 28211
- New Hope Clinical Research
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74136
- Central States Research, LLC
-
-
South Carolina
-
Summerville, South Carolina, United States, 29485
- Palmetto Clinical Research
-
-
Texas
-
Houston, Texas, United States, 77074
- Clinical Trial Network
-
Sugar Land, Texas, United States, 77478
- Mercury Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have a reliable caregiver, an identified adult who, in the opinion of the investigator has sufficient contact to knowledgeably report on the subject's daily cognition, function, behavior, safety, compliance and adherence. Same caregiver(s) must assist the subject throughout the duration of the trial.
- Have a clinical diagnosis of mild-to-moderate AD (Stage 4 or 5) according to the NIA-AA (National Institute of Aging - Alzheimer's Association) criteria at screening
- Meet criteria for mild-to-moderate cognitive impairment with Mini-Mental State Examination (MMSE) score of 14 through 26 at the screening visit.
- Neuroimaging evidence consistent with the diagnosis of AD
- Modified Hachinski </= 4 at screening
- Clinical Dementia Rating is 0.5 to 2.0 at screening and Clinical Dementia Rating - Sum of Boxes is ≥ 3 at screening
- Visual and auditory acuity adequate for neuropsychological testing
- No evidence of hepatic impairment or renal insufficiency
Exclusion Criteria:
- Have a current diagnosis of a significant psychiatric illness per the Diagnostic and Statistical Manual of Mental Disorders V (DSM-V)
- With untreated clinical depression (GDS >/= 6 at screening and baseline)
- Have a current diagnosis of a neurological disease other than AD
- With glycosylated hemoglobin (HbA1c) >/= 7.7 at screening
- With a diagnosis of unstable diabetes
- With clinically significant thyroid disease at screening TSH >5
Have any of the following values at the screening visit:
- ALT and/or AST value that is twice the upper limit of normal
- Total bilirubin value that exceeds 2 mg/dL
- Creatinine level >1.5 mg/dL in men or > 1.4 mg/dL in women
- Positive urinalysis (other than trace result) unless a cause other than renal impairment
- Glomerular filtration rate (GFR) values <54 mL/min/1.73 m2
- Gamma-glutamyl transpeptidase (GGT) value that is twice the upper limit of normal
- Is positive for hepatitis B or anti-hepatitis C virus antibodies at the screening
- Have a history of moderate or severe congestive heart failure, NYHA class III or IV
- Have experienced a previous cardiovascular event (myocardial infarct, by-pass surgery, or PTCA) within the past 12 months prior to the baseline
- Have blood pressure reading at screening that is greater than 160/100 mmHg
- Have a clinically significant unstable illness
- Have a history of HIV infection
- Have a history of alcohol, drug abuse or dependence
- Have a history of cancer within 5 years of the screening
- Have any surgical or medical condition which may significantly alter the absorption of any drug substance
- Females who are pregnant, nursing or of childbearing potential and not practicing effective contraception
- Is required to take excluded medications as specified protocol
- Have a known or suspected intolerance or hypersensitivity to the study drug, closely related compounds
- Resides in hospital or moderate to high dependency continuous care facility
- Are non-ambulatory, or wheelchair-bound
- Have evidence of clinically relevant pathology that in the investigator's opinion could interfere with the study results or put the subject's safety at risk
- History of swallowing difficulties
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo, matching T3D-959 active capsules, is pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules.
Subjects randomized to placebo will ingest three size 0 placebo capsules once per day in the morning.
|
Oral administration once daily in the morning
Other Names:
|
Experimental: 15mg T3D-959
T3D-959 15 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism.
T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma.
The 15 mg strength contains 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules.
Subjects will ingest one size 0, 15mg capsule and two placebo capsules once per day in the morning.
|
Oral administration once daily in the morning
Other Names:
|
Experimental: 30mg T3D-959
T3D-959 30 mg dose: Subjects will ingest two size 0, 15mg capsules and one placebo capsule once per day in the morning.
|
Oral administration once daily in the morning
Other Names:
|
Experimental: 45mg T3D-959
T3D-959 45 mg dose: Subjects will ingest three size 0, 15mg capsules once per day in the morning.
|
Oral administration once daily in the morning
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of T3D-959 on cognition
Time Frame: 28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)
|
Change in cognition as assessed by The Alzheimer's Disease Assessment Scale 11-task cognitive subscale (ADAS-Cog11) from baseline to end of treatment visit, compared to placebo
|
28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)
|
Efficacy of T3D-959 on function
Time Frame: 28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)
|
Change in global function as assessed by Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC) from baseline to end of treatment visit, compared to placebo
|
28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)
|
Safety and tolerability of T3D-959
Time Frame: 28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)
|
Safety will be assessed by 1) AEs, clinical labs, ECG, weight, vital signs 2) Geriatric Depression Scale (GDS) 3)Columbia Suicide Severity Rating Scale (C-SSRS)
|
28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of T3D-959 on executive function
Time Frame: 28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)
|
Change in executive function as assessed by the Digit Symbol Coding Test (DSCT) from baseline to end of treatment visit, compared to placebo
|
28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)
|
Efficacy of T3D-959 on plasma Aβ 42/40 ratio biomarker level
Time Frame: 28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)
|
Change in Aβ 42/40 ratio plasma biomarker from baseline to end of treatment visit, compared to placebo
|
28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Blake Swearingen, MS, T3D Therapeutics, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- T3D959-202
- 1R01AG061122 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Placebos
-
Yiling Pharmaceutical Inc.Completed
-
Nova Scotia Health AuthorityRecruiting
-
Beth Israel Deaconess Medical CenterTerminated
-
Intra-Cellular Therapies, Inc.CompletedBipolar Depression | Major Depressive DisorderUnited States, Bulgaria, Russian Federation, Serbia, Ukraine
-
Josef Smolen, Univ. Prof. Dr.Unknown
-
GE HealthcareSyneos HealthTerminatedChronic Kidney DiseasesUnited States, Spain, Belgium, Canada, Poland, United Kingdom
-
Viela BioCTI Clinical Trial and Consulting ServicesTerminated
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Completed
-
Biohaven Pharmaceuticals, Inc.Active, not recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxias | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 10 | Spinocerebellar Ataxia Type 7 | Spinocerebellar Ataxia Type 8United States, China
-
University Hospital, BrestEli Lilly and CompanyCompletedPolymyalgia Rheumatic (PMR)France